[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibromyalgia-primary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibromyalgia-primary":148},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,97,119],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100444542",false,"NCT05068791","Psilocybin-facilitated Treatment for Chronic Pain","Inclusion Criteria:\n\n1. Female age 25-65;\n2. Widespread musculoskeletal pain for ≥12 months;\n3. Symptoms meeting the American College of Rheumatology (ACR) 2016 revisions to the 2010\u002F2011 Fibromyalgia Diagnostic Criteria;\n4. Participant completes daily report during baseline period (at least 80% completion rate);\n5. Able to attend UAB for all scheduled appointments;\n6. Ability to read\u002Fwrite in English;\n7. No prior hallucinogen use or it will have been at least 3 years since last use of a hallucinogen;\n8. Availability of a friend or family member into whose care the participant can be released (a key responsibility includes driving participants home) following their drug administration session;\n9. A current average daily pain score of at least 5 on a 0-10 scale;\n10. Discontinuation of exclusionary medication occurring at least two weeks and for at least 5 half-lives, whichever is longer, prior to drug administration day.\n\nExclusion Criteria:\n\n1. Males;\n2. Use of opioid medications in the last 60 days;\n3. Regular use of any anti-inflammatory medication (e.g., aspirin, ibuprofen, naproxen);\n4. Use of blood thinning medication;\n5. Use of tricyclic antidepressants, lithium, SSRIs, MAOIs, St. John's Wort, 5-hydroxytryptophan (5-HT), haloperidol, or other antipsychotic medications, mood stabilizers, or medications with serotonin activity;\n6. Daily consumption of grapefruit juice;\n7. Febrile illness or use of antibiotics in the 4 weeks before study commencement;\n8. Planned surgery or procedures during the study period, or operated on in the 4 weeks prior to study commencement;\n9. Planning to move from the Birmingham area in the next 6 months;\n10. Planned vaccination during the study period, or vaccinated in the 4 weeks before study commencement;\n11. Current participation in another treatment trial;\n12. Pregnant or planning to become pregnant within 6 months, or currently breastfeeding;\n13. Significant psychological comorbidity that in the discretion of the investigator compromises study integrity (i.e., presence of a current, clinically significant, untreated or unstable psychiatric condition) and\u002For a baseline HADS depression subscale score of ≥16;\n14. Current or past history of any psychotic disorders;\n15. Current or past history of bipolar I or II disorder;\n16. First or second-degree relatives with any psychotic disorders, or bipolar I or II disorders;\n17. Current suicidal or homicidal ideation (assessed using Columbia-Suicide Severity Rating Scale at each visit);\n18. Diagnosed rheumatologic or auto-immune condition;\n19. Blood or clotting disorder;\n20. Current hypertension (exceeding 140 systolic or 90 diastolic at resting); resting heart rate\\>90\n21. Acute infection (oral temperature \\>100°F);\n22. High-sensitivity c-reactive protein (hs-CRP) ≥ 10mg\u002FL;\n23. Erythrocyte sedimentation rate (ESR) \\> 60 mm\u002Fhr;\n24. Positive rheumatoid factor;\n25. Positive anti-nuclear antibody (ANA);\n26. Levels of thyroid-stimulating hormone or free thyroxine outside UAB Hospital Labs reference values;\n27. Use of UGT1A9, UGT1A10 and aldehyde or alcohol dehydrogenase enzyme inhibitors;\n28. Dependent on any psychoactive drugs other than nicotine and caffeine;\n29. Use of the antiviral drug efavirenz;\n30. Use of PDE-5-Inhibitors, soluble guanylate cyclase (sGC) stimulators;\n31. Severe anemia;\n32. Phenylketonuria, chronic bronchitis, emphysema, asthma, diabetes, liver disease, and mucus with cough or slowed breathing\n33. Use of any medication containing dextromethorphan (e.g., cough suppressants);\n34. Pain due to other conditions or diseases that would complicate study participation or pain reporting.\n35. Use of strong or moderate inhibitors of Cytochrome P450 2D6 (CYP2D6)\n36. Poor metabolizers of CYP2D6 based on genotype","FEMALE","25 Years","65 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential mediators of treatment (e.g., treatment expectations, pain characteristics, personality, beliefs\u002Fcognitions, emotions). Investigators hypothesize psilocybin treatment will significantly reduce symptom severity in fibromyalgia patients.",[25],"Fibromyalgia, Primary",[27,28,29],"psilocybin","fibromyalgia","pain","RECRUITING","2026-03-09",{"date":33,"type":34},"2026-03-11","ACTUAL",{"date":36,"type":34},"2023-11-01",{"date":38,"type":19},"2026-12-31",{"name":40,"class":41},"University of Alabama at Birmingham","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":78,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100497203","NCT05754190","Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA","INCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week or\n  * Average pain interference score of greater than 3 in the past week or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: greater than 6 months\n* Acute pain group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of greater than 3 in the past week\n\n    ○ or\n  * Average pain interference score of greater than 3 in the past week\n\n    ○ or\n  * Average pain distress score of greater than 3 in the past week\n  * Pain duration: less than 3 months\n  * Pain cause: Due to recent surgery, injury, acute illness, or childbirth (within the past 3 months)\n* Healthy control group:\n\n  * Age above 18\n  * Access to a personal smartphone and a stable internet connection\n  * Average pain intensity score of less than 3 in the past week\n  * Average pain interference score of less than 3 in the past week\n  * Average pain distress score of less than 3 in the past week\n  * No surgery, injury, acute illness, or childbirth (within the past 3 months)\n* In person EEG testing \\[Sub-Study only\\]:\n\n  * Same as in General App Study Above and additionally:\n  * Current diagnosis of Fibromyalgia, Chronic Low Back Pain or Failed Back Surgery Syndrome OR\n  * No current or prior history of chronic pain\n  * If participant has chronic low back pain or failed back surgery syndrome: are they planning to have either a radio-frequency ablation, back surgery, or spinal cord stimulation implant in the next few months\n  * If participant has chronic low back pain or failed back surgery syndrome: have they received insurance approval for the procedure?\n  * Ok with EEC\u002FECG measures\n\nEXCLUSION CRITERIA \\[General study\\]\n\n* Chronic pain group:\n\n  * recent injury or surgery unrelated to the pain in the past 3 months\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Acute pain group:\n\n  * History of Chronic Pain (Pain lasting for more than 6 months)\n  * difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n  * Not fluent in English (difficulty understanding questions)\n  * Current primary or metastatic cancer (organic cause of pain)\n* Healthy control group:\n\nHistory of Chronic Pain (Pain lasting for more than 6 months)\n\n* difficulty participating for technical\u002Flogistical issues (e.g., no computer, incompatible smartphone, can't commit to 4 months study participation);\n* Not fluent in English (difficulty understanding questions)\n\n  -In person EEG testing \\[Sub-study only\\]: \\[will interfere with EEG data collection safety or quality\\]:\n* Same as in General App Study Above and additionally:\n* Baldness\n* Pregnancy\n* Dreadlocks\n* Left-handedness\n* Use of a wheelchair\n* Heart failure diagnosis\n* Current or prior experience with acute psychosis or mania\n* implanted pacemaker, neurostimulator or any other head or heart implants\n* require a hearing aid to hear properly\n* claustrophobia\n* metal fragments in the body",true,"ALL","18 Years",{"count":52,"type":19},800,"OBSERVATIONAL","This study relies on the use of a smartphone application (SOMA) that the investigators developed for tracking daily mood, pain, and activity status in acute pain, chronic pain, and healthy controls over four months.The primary goal of the study is to use fluctuations in daily self-reported symptoms to identify computational predictors of acute-chronic pain transition, pain recovery, and\u002For chronic pain maintenance or flareups. The general study will include anyone with current acute or chronic pain, while a smaller sub-study will use a subset of patients from the chronic pain group who have been diagnosed with chronic low back pain, failed back surgery syndrome, or fibromyalgia. These sub-study participants will first take part in one in-person EEG testing session while completing simple interoception and reinforcement learning tasks and then begin daily use of the SOMA app. Electrophysiologic and behavioral data from the EEG testing session will be used to determine predictors of treatment response in the sub-study.",[56,57,58,25,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77],"Chronic Pain","Acute Pain","Post Operative Pain","Fibromyalgia, Secondary","Fibromyalgia","Irritable Bowel Syndrome","Chronic Headache Disorder","Chronic Migraine","Chronic Pelvic Pain Syndrome","Temporomandibular Joint Disorders","Endometriosis-related Pain","Arthritis","Chronic Low-back Pain","Failed Back Surgery Syndrome","Post Herpetic Neuralgia","Neuropathic Pain","Painful Diabetic Neuropathy","Painful Bladder Syndrome","Trauma-related Wound","Trauma, Multiple","Chronic Pain Syndrome","Chronic Shoulder Pain",[79,80,81,82,83,84,85,86,87],"digital health","e-health","smartphone application","chronic pain","acute pain","symptom tracking","experience sampling methodology","ecological momentary assessment","pain self-management","2025-09-16",{"date":90,"type":34},"2025-09-19",{"date":92,"type":34},"2023-06-20",{"date":94,"type":19},"2026-05-30",{"name":96,"class":41},"Brown University",{"id":98,"slug":4,"hasResults":10,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":10,"sex":14,"minAge":50,"maxAge":16,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":42},"100548726","NCT06424743","Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training","Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training: Clinical Trial Randomized Crossover","Inclusion Criteria:\n\n* Women aged 18 to 65\n* Have a diagnosis of fibromyalgia according to the ACR 2016 criteria\n\nExclusion Criteria:\n\n* Have performed resistance training in the last 6 months\n* Having another associated rheumatic condition\n* Have a trip or appointment scheduled that requires absence for the next 4 (four) weeks from the start of the survey;\n* Women with musculoskeletal injuries in the upper and\u002For lower limbs\n* Have heart problems that prevent maximal efforts and submaximums",{"count":104,"type":19},36,[106],"NA","Fibromyalgia is a painful syndrome of unknown etiology, which affects 2% of world population, with symptoms such as: pain, unrefreshing sleep, fatigue and mood disorders. It is already established in the literature that resistance training is part of the non- pharmacological treatment for patients with fibromyalgia. The big gap is about the quantity adequate and\u002For recommended exercise volume, despite some studies with exercise volumes different resistance trainings show improvements, we do not have a direction, besides We still do not know whether there is a preference for these patients in different resistance training volumes.",[25,56,109],"Exercise Addiction","2025-07-19",{"date":112,"type":34},"2025-07-23",{"date":114,"type":34},"2025-07-01",{"date":116,"type":19},"2026-12-01",{"name":118,"class":41},"Universidade Federal do Rio Grande do Norte",{"id":120,"slug":4,"hasResults":10,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":10,"sex":49,"minAge":50,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":128,"conditions":129,"keywords":135,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":42},"100426368","NCT04832100","Bio-significance of LPC16:0 in Fibromyalgia","A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia","Inclusion Criteria:\n\n1\\. Clinical diagnosis of fibromyalgia\n\nExclusion Criteria:\n\n1. Systemic rheumatological or immune disorders (e.g., systemic lupus erythematosus, inflammatory myositis),\n2. Systemic use of corticosteroids,\n3. Pregnancy,\n4. Chronic diseases under poor control\n5. Malignancies.","70 Years",{"count":127,"type":19},245,"Fibromyalgia (FM) is a very common but mysterious pain disorder characterized by chronic widespread muscular pain. Fatigue, anxiety and depression are common comorbidities. The syndrome is commonly associated with several symptoms, including fatigue, sleeping disturbance, cognitive impairment, and comorbid pain syndrome, especially irritable bowel symptoms and temporomandibular disease. Anxiety and depression are common psychiatric co-morbidies. Daily stress is believed to trigger or aggravate pain conditions. These symptoms can markedly affect patients' quality of life, and even lead to disability. So far, the etiology and pathogenesis are largely unknown, and diagnostic biomarkers and curative treatment remain to be developed. Recent technological advances enable scientists to explore mechanisms by genetic, transcriptomic, proteomic, and metabolomic researches. However, no definitive result has been concluded for clinical practice so far.\n\nIn this study, the investigators use tailored questionnaires to evaluate fibromyalgia and associated symptoms, including numeric rating scale for soreness, widespread soreness index, Fibromyalgia impact questionnaire, Hospital Anxiety and Depression Scale, and perceived stress scale. The investigators also use metabolomics and lipidomic approach to probe the potential pathophysiology of fibromyalgia. In our prior translation research (PMID: 32907805), the investigators found that excessive LPC16:0 resulting from lipid oxidization inflicts psychological stress-induced chronic non-inflammatory pain via activating ASIC3. In this content, our prior translational research identified a potential nociceptive ligand that causes fibromyalgia symptoms, which is likely to function as biomarkers for diagnosis or disease monitor. In the current clinical investigation, the investigators aim to reversely translate the novel findings in animal studies and validate the bio-significance of LPC16:0 for fibromyalgia with clinical approaches.",[25,130,131,132,133,134],"Pain","Soreness, Muscle","Oxidative Stress","Metabolomics","Lipidomics",[136,28,29,137,138],"lysophosphotidylcholine","soreness","metabolomics","2025-06-22",{"date":141,"type":34},"2025-06-26",{"date":143,"type":34},"2021-06-01",{"date":145,"type":19},"2027-06-30",{"name":147,"class":41},"Kaohsiung Medical University Chung-Ho Memorial Hospital",""]